Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • UCLA • HR+ • NCI-CCC Breast Tumor Board Question
What would you use as adjuvant endocrine therapy for a patient who developed an invasive, hormone receptor positive breast cancer while on raloxifene for almost a decade prior?
Out of curiosity, I did tumor testing, and she does not have an activating ESR1 mutation.
Answer from: Medical Oncologist at Academic Institution
In this situation I would use an aromatase inhibitor if possible. One would not expect an ESR1 activating mutation to be readily detected after treatment with a SERM, since estrogen deprivation rather than receptor blockade enriches for ESR1 mutant clones.
Sign in or Register to read more